Stock Events

Stock Events

Canton Strategic 

$3.26
0
+$0.02+0.62% Thursday 20:00

Statistics

Day High
3.34
Day Low
3.12
52W High
9.08
52W Low
0.95
Volume
121,684
Avg. Volume
864,165
Mkt Cap
114.25M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

3JunExpected
Q3 2025
Q4 2025
Next
-0.43
-0.43
-0.42
-0.42
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
0Revenue
-24.4MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CNTN. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Moderna
MRNA
Mkt Cap10.61B
Moderna, Inc. is a competitor because it also focuses on mRNA-based therapies, potentially overlapping with Tharimmune's immunotherapy approaches.
BioNTech
BNTX
Mkt Cap24.99B
BioNTech SE operates in the field of mRNA technology for developing vaccines and therapeutics, directly competing with Tharimmune's technology platform.
Novavax
NVAX
Mkt Cap1.36B
Novavax, Inc. competes in the vaccine development space, particularly in the development of vaccines for infectious diseases, which may overlap with Tharimmune's focus areas.
Pfizer
PFE
Mkt Cap140.15B
Pfizer Inc. has a broad portfolio in vaccines and biopharmaceuticals, making it a competitor in various therapeutic areas that Tharimmune may target.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences, Inc. is involved in the development of antiviral drugs and other treatments that could compete with Tharimmune's immunotherapeutic approaches.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals, Inc. is known for its work in immunology and infectious diseases, areas that Tharimmune may also be exploring.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca PLC has a diverse biopharmaceutical portfolio, including treatments for cancer and other diseases, potentially competing with Tharimmune's research and development.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson operates in various healthcare sectors, including pharmaceuticals with a focus on immunology, making it a competitor to Tharimmune.
Merck
MRK
Mkt Cap214.76B
Merck & Co., Inc. has a strong presence in the development of vaccines and cancer therapies, areas that may intersect with Tharimmune's interests.
Sanofi
SNY
Mkt Cap124.45B
Sanofi is involved in the development of vaccines and treatments for immune system diseases, competing with Tharimmune in the immunotherapy space.

About

Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.
Show more...
CEO
ISIN
US4327053090

Listings

XNAS
US
THAR
BOATS
BOATS
THAR.BOATS
XNAS
US
CNTN
MX
MX
CNTN.MX

0 Comments

Share your thoughts

FAQ

What is Canton Strategic stock price today?▼
The current price of CNTN is $3.26 USD — it has increased by +0.62% in the past 24 hours. Watch Canton Strategic stock price performance more closely on the chart.
What is Canton Strategic stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Canton Strategic stocks are traded under the ticker CNTN.
What is Canton Strategic market cap?▼
Today Canton Strategic has the market capitalization of 114.25M
When is the next Canton Strategic earnings date?▼
Canton Strategic is going to release the next earnings report on June 03, 2026.
What is Canton Strategic revenue for the last year?▼
Canton Strategic revenue for the last year amounts to 0 USD.
What is Canton Strategic net income for the last year?▼
CNTN net income for the last year is -24.4M USD.
When did Canton Strategic complete a stock split?▼
Canton Strategic has not had any recent stock splits.